EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, UTHR:

05 Sep 2025
LAST:

400.5

CHANGE:
 20.05		OPEN:
375.6		HIGH:
401.6		ASK:
129.6		VOLUME:
924.6K
CHG(%):
5.27		PREV:
380.5		LOW:
375.6		BID:
0.1		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Sep 25375.6401.6375.6400.5924.6K
04 Sep 25395.6396.5375.9380.51.4M
03 Sep 25402.6410.0385.0391.51.68M
02 Sep 25419.6437.0402.3404.83.14M
29 Aug 25307.2308.0303.1304.8418.7K
28 Aug 25305.6309.0302.2307.2749.9K
27 Aug 25308.0312.4305.0305.3583.4K
26 Aug 25306.8309.3304.5309.21.31M
25 Aug 25310.7312.6304.8305.4659.9K
22 Aug 25310.0315.7308.3312.2576.4K

COMPANY PROFILE

Name:
About:United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Sector:Healthcare
Address:1000 Spring Street, Silver Spring, MD, United States, 20910
Website:https://www.unither.com
CUSIP:91307C102
CIK:0001082554
ISIN:US91307C1027
FIGI:BBG000BV4XJ1
LEI:5299005C4HZL4UWROC14

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:12.22
Price to Book:1.98
Price to Sales:4.60
EBITDA:1.597B
Shares:45.23M
Market Cap:18.114B

TECHNICAL INDICATORS

MA5:376.40
MA10:342.14
MA20:325.21
MA50:307.07
MA100:304.14
MA200:324.04
STO9:72.44
STO14:72.44
RSI14:74.59
WPR14:-4.29
MTM14:86.42
ROC14:0.28
ATR:19.32
Week High:436.95
Week Low:303.09
Month High:436.95
Month Low:291.22
Year High:436.95
Year Low:266.98
Volatility:23.21

RECENT SPLITS

Date Ratio
23 Sep 20092-1